Literature DB >> 12411719

Latex allergy and sensitization in children with spina bifida.

Andrzej Obojski1, Jacek Chodorski, Wojciech Barg, Wojciech Medrala, Andrzej M Fal, Józef Małolepszy.   

Abstract

BACKGROUND: The purpose of this study was to investigate the prevalence rate of latex sensitization and latex allergy among children with spina bifida and to evaluate risk factors for natural rubber latex hypersensitivity.
METHODS: A total of 34 children between 2.5 and 17 years of age participated in the study. Participants completed a questionnaire and underwent skin prick tests with latex, common aeroallergens and food allergens as well as measurements of specific IgE to latex and food allergens (RAST CAP).
RESULTS: The prevalence of latex sensitization and latex allergy was estimated to be 32.4 and 18.8%, respectively. The most common reported clinical manifestation of latex allergy was urticaria. Three out of six symptomatic patients reported anaphylactic reactions.
CONCLUSION: We found that major risk factors for latex sensitization were atopy and a history of numerous operations. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12411719     DOI: 10.1159/000066219

Source DB:  PubMed          Journal:  Pediatr Neurosurg        ISSN: 1016-2291            Impact factor:   1.162


  3 in total

1.  Latex sensitisation and allergy in children with myelomeningocele.

Authors:  C Rendeli; E Nucera; E Ausili; F Tabacco; C Roncallo; E Pollastrini; M Scorzoni; D Schiavino; M Caldarelli; D Pietrini; G Patriarca
Journal:  Childs Nerv Syst       Date:  2005-02-10       Impact factor: 1.475

2.  Latex allergy guidelines for people with spina bifida.

Authors:  Veronica Meneses; Sarah Parenti; Heather Burns; Richard Adams
Journal:  J Pediatr Rehabil Med       Date:  2020

3.  Cross-Reactivity between Schistosoma mansoni Antigens and the Latex Allergen Hev b 7: Putative Implication of Cross-Reactive Carbohydrate Determinants (CCDs).

Authors:  Michael J Doenhoff; Marwa El-Faham; Susan Liddell; Heidi R Fuller; Ronald G Stanley; Gabriele Schramm; Joseph E Igetei
Journal:  PLoS One       Date:  2016-07-28       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.